Welcome to our dedicated page for Olema Pharmaceuticals news (Ticker: OLMA), a resource for investors and traders seeking the latest updates and insights on Olema Pharmaceuticals stock.
Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other endocrine-driven cancers. The news flow around OLMA reflects its active clinical development program, capital markets activity, and ongoing corporate updates.
Investors and followers of Olema’s news can expect frequent updates on its lead product candidate, palazestrant (OP-1250), an orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) being evaluated in ER+/HER2- metastatic breast cancer. Company announcements include progress in pivotal Phase 3 trials such as OPERA-01 and OPERA-02, data presentations from Phase 1b/2 studies of palazestrant in combination with ribociclib, and details on additional Phase 1/2 combination studies with agents like palbociclib, alpelisib, everolimus, and atirmociclib.
Olema’s news stream also covers pipeline developments for OP-3136, a KAT6 inhibitor in Phase 1 clinical evaluation as monotherapy and in combination with fulvestrant and palazestrant in advanced solid tumors. Regulatory and collaboration milestones, such as clinical trial agreements with Pfizer to study palazestrant plus atirmociclib, are disclosed through press releases and SEC filings.
In addition, Olema regularly reports financial and operating results, underwritten public offerings of common stock under its shelf registration on Form S-3, and inducement grants of stock options to new employees under its 2022 Inducement Plan. The company also announces participation in healthcare and investor conferences, where it presents updates on its clinical programs and strategy. Readers who follow OLMA news gain insight into trial progress, collaboration agreements, financing activities, and other corporate events that shape Olema’s development as a clinical-stage oncology company.
Olema Oncology (NASDAQ: OLMA) will present initial clinical data for OP-3136 from a Phase 1 first-in-human study and a trial-in-progress poster for the Phase 3 OPERA-02 trial at the ASCO Annual Meeting, May 29–June 2, 2026 in Chicago.
The OP-3136 poster (Abstract 3088, Poster 225) is scheduled for May 30, 2026, 1:30pm–4:30pm CT; the OPERA-02 poster (Abstract TPS1152, Poster 261b) is scheduled for June 1, 2026, 1:30pm–4:30pm CT.
Olema Oncology (Nasdaq: OLMA) announced preclinical AACR posters showing palazestrant fully recruits corepressor NCoR1 to achieve complete estrogen receptor antagonism and robust in vitro anti-tumor activity.
Data also show OP-3136, a KAT6 inhibitor, synergizes with palazestrant in ER+/HER2- models; palazestrant is in two Phase 3 trials and OP-3136 is enrolling in Phase 1. Posters presented April 20, 2026 at AACR.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 188,500 shares, effective April 1, 2026, under the company's 2022 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $15.12, equal to the last reported Nasdaq sale price on April 1, 2026.
Olema Oncology (Nasdaq: OLMA) will present two preclinical posters at the AACR Annual Meeting in San Diego, April 17-22, 2026. Both presentations are scheduled on April 20, 2026 in the session "Experimental and Molecular Therapeutics: Cellular Responses to Anticancer Drugs."
Poster 2950 reports that palazestrant recruits corepressor NCoR1 leading to complete ERα antagonism; poster 2949 describes palazestrant plus OP-3136 synergistically downregulating proliferation and metastasis gene signatures.
Olema Oncology (Nasdaq: OLMA) reported Q4 and full-year 2025 results, highlighting late-stage progress for palazestrant and early data plans for OP-3136. The company raised approximately $218.5 million in a follow-on offering and ended 2025 with $505.4 million in cash, cash equivalents, and marketable securities.
Operationally, OPERA-01 top-line data are expected in fall 2026, OPERA-02 enrollment is advanced, a Phase 1b/2 study with Pfizer began, and OP-3136 initial clinical data are anticipated in Q2 2026.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 205,000 shares, effective March 2, 2026.
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $24.02, equal to the last reported Nasdaq sale price on March 2, 2026.
Olema Oncology (Nasdaq: OLMA) announced that CEO Sean P. Bohen, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 p.m. ET. A live webcast and recording will be available on Olema’s investor relations site, subject to event host permissions.
Olema Oncology (Nasdaq: OLMA) announced participation in three investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11 (New York, fireside chat), Citi’s Virtual Oncology Leadership Summit on Feb 19 (virtual, fireside chat), and Oppenheimer Healthcare Life Sciences on Feb 26 (virtual, fireside chat). Live webcasts and recordings will be posted at Olema's investor relations site, as permitted by event hosts.
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to two new employees to purchase an aggregate of 24,000 shares, effective February 2, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term, and an exercise price of $25.65.
The awards were approved by the Compensation Committee and issued under the company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA) announced that Shane Kovacs, Chief Operating and Financial Officer, is departing effective January 30, 2026 to pursue new opportunities and will remain as a consultant through August 1, 2026. The company has begun an immediate search for a successor, and President and CEO Sean P. Bohen, M.D., Ph.D., has assumed the role of interim Principal Financial Officer.
The release notes Kovacs helped advance palazestrant to late-stage clinical development, build a finance team, and establish a strong capital position.